Pinned Tweet
Great to have our CEO @RosDeegan providing her insights on the challenges and opportunities facing the UK Healthcare and Life Sciences sector at the Prime Minister @RishiSunak 2024 Business Council.
Read the summary HERE:
gov.uk/government/news/pm-me…
#lifescience #ukbiotech #growth
OMass Therapeutics retweeted
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Oxford, UK based @omasstx, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF.
Full video: biotechtv.com/post/omass-the…
OMass Therapeutics retweeted
Many thanks to Prof Carol Robinson and Dr Idlir Liko for talking to us about their entrepreneurial journey from an @OxfordChemistry lab to founding drug discovery company OMass.
@omasstx @CVR_Research @OxUInnovation
OMass Therapeutics retweeted
Life sciences plays an important role in our society and economy, but it often struggles to secure funding.
Ahead of our 10th anniversary, we spoke to Ros Deegan, CEO of @omasstx, about their journey and the impact of investment on life sciences.
#ThePowerOf10
OMass Therapeutics retweeted
Publication Alert 🚨
Check out @C_Lutomski new paper in @NatureChemistry: Defining proteoform-specific interactions for drug targeting in a native cell signalling environment
#MassSpec #TopDown #Native @KavliOxford @KavliFoundation @WolfsonCollege
nature.com/articles/s41557-0…
We have, in collaboration with @KavliOxford , @UniofOxford and @thermofisher , developed a novel method that expands the capabilities of our core technology, OdyssION.
In this new publication in Nature Chemistry, we show protein-ligand interactions can be identified at the proteoform level using samples derived from native cell environments.
Access the full article here: shorturl.at/BRrUG
#DrugDiscovery #MassSpec
Our Vice President of Pharmacology and incoming CSO Steven Charlton will be presenting at the GPCRs-Targeted Drug Discovery #Summit taking place in London from 26-28 November.
Steven’s presentation, titled ‘Optimising Binding Kinetics Yields Insurmountable MC2 Receptor Antagonists for the Treatment of Diseases of ACTH Excess’ will take place at 4pm GMT on 27th November at 15Hatfields.
For more information, visit: gpcrs-europe.com/speaker/ste…
Our CEO @RosDeegan was this year’s Women-Led Business Leader of the Year at the @lifestarsawards!
Under Ros’ leadership, we are excited to see what the next year holds!
#awards #drugdiscovery #masspec #biotech #lifescience #innovation #leadership
Our CEO @RosDeegan, CBO Melissa Faris and SVP of Finance and Operations Hsin Loke will be attending this year’s @Jefferies London Healthcare #Conference taking place from 19-21 November.
If you’d like to connect, please contact: [email protected]
OMass Scientists @DTransporterguy Shahid Rehan and @rema2642 Rei Matsuoka will be presenting at the 32nd Protein Structure Determination in Industry (#PSDI) 2024 conference, taking place in Paris from 10-12 November.
Shahid will present on ‘Lipid Binding and Drug Discovery for the Lysosomal Solute Carrier SLC15A4’, while Rei’s presentation will focus on ‘Structural biology at OMass Therapeutics’.
For more information, visit: synchrotron-soleil.fr/en/eve…
#DrugDiscovery #Structuralbiology
Our publication in @Nature Communications highlights the power of hydrogen deuterium exchange #HDX for studying protein dynamics showing how HDX-MS helps understand drug mechanisms and the importance of early compound property insights for developing SAR.
nature.com/articles/s41467-0…
A big welcome to Juliane Schwaderer who joins our team as Director of R&D Project Management. Our team continues to expand as we enter an exciting stage of development.
To learn more about OMass, visit our website: omass.com/
#drugdiscovery #immunology #MassSpec
Our Senior Director of Computational Chemistry Ben Tehan will be speaking at the @MgmsUpdates Computational Drug Design #Symposium on 4 October in Stevenage.
Ben’s presentation, titled ‘Molecular Dynamics in a Mass Spectrometry Company’ is at 2pm BST.
Excited to announce the candidate nomination of our lead program targeting the melanocortin-2 (MC2) receptor for the treatment of conditions related to ACTH excess.
Read the full press release here: omass.com/2024/10/01/omass-t…
Learn more about the potential of our MC2 program to treat Cushing’s disease and congenital adrenal hyperplasia in a blog by our CSO, @aj8791, here: omass.com/blog/too-much-of-a…
#nomination #drugdiscovery #masspec #biotech
Our Senior Scientists Alex Wilkinson and Dillon Popat will be delivering poster presentations at the @ELRIG_UK – Drug Discovery 2024 taking place in London from 2-3 October.
To view the full programme visit: elrig.org/wp-content/uploads…
#ELRIG #Conference #ELRIGDD24 #DrugDiscovery
We are delighted to announce three key #appointments to our development team based in the US and UK.
Steve Griffen joins as VP of Clinical Development, @AngelaHecyk joins as Director of Clinical Operations & Stuart Hadley joins as Senior Director of CMC.
omass.com/2024/10/01/omass-t…
Our Principal Scientist, Christine Oswald & Senior Scientist, Raphael Reinbold will be attending the 9th @RSC_BMCS / @SCIupdate Symposium on GPCRs in Medicinal Chemistry taking place from 2nd – 4th October in Verona, Italy.
Get in touch to find out more about our #GPCR programs.
